Johnson & Johnson podría ser menos eficaz contra la variante deltanews2021-07-24T13:00:07+00:00July 24th, 2021|The New York Times|
Headache Research Advances Though Cures Are Elusivenews2021-07-23T09:00:14+00:00July 23rd, 2021|The New York Times|
Biogen’s Aduhelm Sales Total $2 Million in Second Quarternews2021-07-22T21:10:02+00:00July 22nd, 2021|The New York Times|
Drug Distributors and J.&J. Reach $26 Billion Deal to End Opioids Lawsuitsnews2021-07-21T23:24:01+00:00July 21st, 2021|The New York Times|
J.&J. Vaccine May Be Less Effective Against Delta, Study Suggestsnews2021-07-20T21:20:49+00:00July 20th, 2021|The New York Times|
States and Cities Near Tentative $26 Billion Deal in Opioids Casesnews2021-07-20T21:16:11+00:00July 20th, 2021|The New York Times|
Drug Companies to Pay N.Y. More Than $1 Billion to Settle Opioid Lawsuitnews2021-07-20T20:40:18+00:00July 20th, 2021|The New York Times|
How an Unproven Alzheimer’s Drug Got Approvednews2021-07-20T02:12:00+00:00July 20th, 2021|The New York Times|
Covid Vaccine Booster Shots Are Coming. Are they Needed?news2021-07-18T15:00:08+00:00July 18th, 2021|The New York Times|
